Skip to main content
OpenTrials
Completed

NCT Number: NCT02734264

Field Studies of Amebiasis in Bangladesh

The purpose of this study will be to investigate the incidence of both Amebiasis and cryptosporidiosis in Bangladeshi children and examine genetic variation in innate and adaptive immunity with respect to these infections. Novel diagnostics to these infections will also be investigated.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Amebiasis Cryptosporidium Infections Parasitic Diseases Protozoan Infections

Age range

Up to 7 day

Sex eligibility

All sexes

Study type

Observational

Primary location

The International Centre for Diarrhoeal Disease Research, Bangladesh

Dhaka, Bangladesh

About this study

Entamoeba histolytica infection results from ingestion of the cyst of Entamoeba histolytica from fecally-contaminated food or water. Local invasion results in amebic dysentery and metastasis to amebic liver abscess. The diagnosis of intestinal amebiasis is ideally made using an E. histolytica-specific stool antigen detection test or using real-time polymerase chain reaction (PCR). The two major clinical syndromes of amebiasis are amebic colitis and amebic liver abscess. Together they are estimated to result in 50 million cases of colitis and liver abscess and 100,000 deaths worldwide each year. In developing countries, colonization with E. histolytica has been observed in 5% or more of poor children. Patients with amebic colitis typically present with a several week history of gradual onset of abdominal pain and tenderness, diarrhea and bloody stools (dysentery). The pathological lesions in the colon include ulceration of the intestinal epithelium and invasion into the lamina propria by trophozoites. Inflammation, with infiltrating neutrophils and mononuclear lymphocytes is pronounced, but inflammatory cells near the amebae are killed with pyknotic nuclei characteristic of apoptotic death. Amebic liver abscess is a rare form of the disease that is almost exclusively limited to adult males.

Cryptosporidiosis in humans is caused primarily by two species, Cryptosporidium parvum and C. hominis. There are annually approximately 1.4 cases/100,000 in the United States reported to the Centers for Disease Control. Infection results from ingestion of fecally contaminated water or food containing the infectious oocyst form. Sporozoites are released from the oocyst in the small intestine and attach to the epithelial cell surface. Upon invasion of the epithelial cells the parasite undergoes both the sexual and asexual stages of the life cycle. Infection with C. parvum in a normal host leads to days to several weeks of non-bloody diarrhea.

In many people E. histolytica and Cryptosporidia infections resolve without symptoms. A major emphasis of this study will be to study the host, environment, and parasite factors controlling susceptibility to E. histolytica and Cryptosporidia infection and disease, to begin to answer the question of why all infections do not cause disease. At the same time, want to improve diagnostic techniques for these diseases.

This study will continue a cohort of 420 children (average age now 10.5 years) that the research team has been following since birth and measure the incidence of amebiasis and cryptosporidiosis prospectively. In addition, 500 live births will be enrolled into an existing cohort.

This work has several objectives. The first objective is to compare current "gold-standard" diagnostic techniques for these diseases with newer antigen detection and polymerase chain reaction techniques. The second objective is to delineate the protective role of innate and acquired immunity to E. histolytica. The investigators hypothesize that protective immunity is mediated both by innate immune responses initiated via Toll-like Receptor stimulation and acquired responses including mucosal immunoglobulin A (IgA) and systemic Interferon-γ. Acquired immune responses (peripheral blood mononuclear cell cytokine production and fecal IgA anti-cross reacting determinant) during amebic and cryptosporidial infection and disease will be determined in the children in the cohort. The third objective is to test for the association of genetic polymorphisms in innate and acquired immune genes with incidence of amebiasis. The investigators hypothesize that common genetic polymorphisms in genes of the innate and acquired immune system influence susceptibility to E. histolytica and Cryptosporidia infection or disease. The final objective is to test the role of human genetic polymorphisms and microbiome in protection from undernutrition. Genome wide scans and microbiome compositional analyses will be performed on children to determine if the nutritional status of the child correlates with these measurements.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Resident of Mirpur, Dhaka, Bangladesh

Exclusion criteria

  • Mother under 65 years old

Treatment and study plan

Primary outcomes

  1. Incidence of Amebiasis and Cryptosporidium infection

    Time frame: Birth to 5 years

Secondary outcomes

  1. Peripheral blood mononuclear cell Interleukin (IL)-1β stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  2. Peripheral blood mononuclear cell IL-2 stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  3. Peripheral blood mononuclear cell IL-4 stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  4. Peripheral blood mononuclear cell IL-5 stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  5. Peripheral blood mononuclear cell IL-6 stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  6. Peripheral blood mononuclear cell IL-7 stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  7. Peripheral blood mononuclear cell IL-8 stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  8. Peripheral blood mononuclear cell IL-10 stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  9. Peripheral blood mononuclear cell IL-12(p70) stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  10. Peripheral blood mononuclear cell IL-12(p40) stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  11. Peripheral blood mononuclear cell IL-13 stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  12. Peripheral blood mononuclear cell IL-17 stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  13. Peripheral blood mononuclear cell interferon-γ stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  14. Peripheral blood mononuclear cell granulocyte-macrophage colony-stimulating factor stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  15. Peripheral blood mononuclear cell tumor necrosis factor-α stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  16. Peripheral blood mononuclear cell tumor necrosis factor-β stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  17. Peripheral blood mononuclear cell granulocyte-colony stimulating factor stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  18. Peripheral blood mononuclear cell macrophage inflammatory protein (MIP)-1 β stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  19. Peripheral blood mononuclear cell MIP-1 α stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  20. Peripheral blood mononuclear cell monocyte chemotactic protein-1 stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  21. Peripheral blood mononuclear cell eotaxin stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  22. Peripheral blood mononuclear cell fibroblast growth factor basic stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  23. Peripheral blood mononuclear cell vascular endothelial growth factor stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  24. Peripheral blood mononuclear cell "regulated on activation, normal T expressed and secreted" (RANTES) stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  25. Peripheral blood mononuclear cell leptin stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  26. Peripheral blood mononuclear cell epithelial neutrophil activating peptide (ENA)-78 stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  27. Peripheral blood mononuclear cell nerve growth factor stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  28. Peripheral blood mononuclear cell inducible protein-10 stimulation studies

    Time frame: Birth to 5 years

    Investigators plan to obtain blood for cytokine analysis from children when they do not have E. histolytica infection and are free of diarrheal disease. Investigators also plan to obtain blood for cytokine analysis from children within 48 hours of the diagnosis of E. histolytica infection or disease.

  29. Fecal immunoglobulin-A

    Time frame: Birth to 5 years

    This will be collected as paired samples. One sample will be from each episode of Amebiasis diarrhea and will paired with a stool from that child when they have no Amebiasis detected in the stool and are without acute diarrhea.

  30. Fecal immunoglobulin-G anti-cross-reacting determinant

    Time frame: Birth to 5 years

    This will be collected as paired samples. One sample will be from each episode of Amebiasis diarrhea and will paired with a stool from that child when they have no Amebiasis detected in the stool and are without acute diarrhea.

  31. Single nucleotide polymorphism analysis of innate and adaptive immunity

    Time frame: Once; between birth and day 7 of life.

  32. Genome wide association scan

    Time frame: Once, at 5 years of age

  33. Fecal microbiome determination via 16s ribosomal deoxyribonucleic acid (rDNA)

    Time frame: Birth to 5 years

  34. Length/Height in centimeters

    Time frame: Birth to 5 years

  35. Weight in grams

    Time frame: Birth to 5 years

Sponsors and collaborators

Lead sponsor

University of Virginia

Other

Collaborators

  • International Centre for Diarrhoeal Disease Research, Bangladesh

Registry information

Official study title

Field Studies of Human Immunity to Amebiasis in Bangladesh: A Prospective Study of Children Ages 0-17 Years

Important dates

Study start
2008
Primary completion
2014
Study completion
2014
First posted
Apr 12, 2016
Registry last updated
Oct 26, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.